Labcorp to buy BioReference Health assets from OPKO for $722M

OPKO Health agreed to sell select assets of its BioReference Health subsidiary to Labcorp for $722 million in cash at closing, adjustable based on revenues, plus up to $150 million in earnouts tied to the 4Kscore prostate cancer test. Labcorp gets clinical, women's health, urology and corrections testing businesses and over 80 patient service centers.

Why it matters: The deal extends Labcorp's testing footprint while letting OPKO monetize its diagnostics business; it still needs regulatory approvals.